SCHEDULE 13G: Armistice Capital Discloses Nearly 10% Passive Stake in CERO Therapeutics Holdings
Beneficial Ownership Disclosure
Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% passive beneficial ownership stake in CERO Therapeutics Holdings, Inc. as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively the 'Reporting Persons', have filed a Schedule 13G indicating beneficial ownership of CERO Therapeutics Holdings, Inc. common stock.
- The Reporting Persons collectively beneficially own 584,548 shares of CERO Therapeutics Holdings, Inc. common stock.
- This ownership represents 9.99% of the issuer's class of securities.
- Both Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over all 584,548 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as the disclosure of a significant institutional stake can be viewed favorably by the market, implying investor confidence, although the filing itself is purely informational and passive.
Positives
- A significant institutional investor, Armistice Capital, LLC, has disclosed a nearly 10% stake, potentially signaling confidence in CERO Therapeutics Holdings, Inc.
Industry Context
This filing indicates a significant passive investment by an institutional fund in a therapeutics company. Such disclosures are common in the biotechnology and pharmaceutical sectors, where investment firms often take positions in companies with promising pipelines or technologies.
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by Armistice Capital, LLC may be viewed positively, potentially increasing investor confidence in CERO Therapeutics Holdings, Inc.
- Company Management: Awareness of a large passive institutional investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold crossed). |
| 05/15/2025 | Date of filing and signature of the Schedule 13G statement. |
Keywords
CERO Therapeutics Holdings, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, Biotechnology, Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.